Moderna shares see a jump — What is fueling the stock rise

Traders Union
All News
Financial News
Moderna rises 2.73% today to $54.77

Highlights

Moderna settled global LNP technology litigation for $950 million upfront and up to $1.3 billion more, gaining key licensing rights for infectious diseases.
The company reported $1.9 billion in 2025 revenue and executed $2.2 billion in cost cuts, exiting the year with $8.1 billion in cash.
Shares trade with strong bullish momentum; price is likely to stay between $52.13 and $53.90 over the coming week barring a breakout.

Settlement windfall and regulatory wins bolster cash, sentiment turns positive

In early March 2026, Moderna reached a global settlement with Genevant Sciences and Arbutus Biopharma regarding the alleged unauthorized use of lipid nanoparticle (LNP) technology in its COVID-19 vaccines, agreeing to pay $950 million upfront and up to $1.3 billion more depending on an appellate ruling. As part of the settlement, Moderna secured a global non-exclusive license for infectious disease applications. The company also reported $1.9 billion in 2025 revenues, executed $2.2 billion in cost reductions, held $8.1 billion in cash, and received a positive European Medicines Agency opinion on its mCOMBRIAX combination vaccine for influenza and COVID-19.

Anton Kharitonov, expert at Traders Union, views Moderna’s technical picture as bullish but prone to exhaustion. He notes the rally sits atop strong moving average support, yet sees a gap between price momentum and oscillators. The significant cash outflow from the settlement and dependence on a positive appellate ruling add pressure despite recent revenue gains. Kharitonov warns that temporary buying dominance could give way to profit-taking. "I remain cautious here — the risk of a sharp pullback increases if $52.13 is broken and any negative news emerges."

Viktoras Karapetjanc, expert at Traders Union, sees Moderna in a robust uptrend supported by strong fundamentals. He highlights the global settlement and new licensing terms as a strategic win, unlocking future growth potential. High liquidity and decisive cost management confirm institutional confidence. Macro conditions and regulatory milestones bolster the bullish structure. "Further growth is expected as Moderna leverages settlements and expansion, making the market environment highly constructive for investors."

Bullish signals persist as overbought oscillators hint at consolidation

The nearest dynamic support is the Ichimoku Kijun at $48.11, while resistance may be encountered near the MA-50 or the next round level above the current price. Momentum readings on D1 remain positive, with both MACD and ADX signaling continued upside strength. RSI sits at 56.91 and Stoch RSI is in oversold territory, reflecting healthy momentum but also hinting at an early pause for consolidation; CCI is neutral. BBP suggests intraday buying dominance as it shows overbought conditions, which is consistent with the daily gain of $1.46 or 2.73% — there was no major gap between yesterday’s close and today’s open. MRNA last traded near the upper boundary of today’s range ($53.83 – $54.74), reflecting moderate volatility and strength toward the session’s highs. There is some divergence between overbought oscillators and oversold Stoch RSI, suggesting the rally may be due for a brief cooling period, yet daily price action and momentum indicators confirm underlying bullishness.

Previously it was reported that while Moderna exhibited generally bullish technical momentum, conflicting signals from various indicators highlighted the potential for near-term uncertainty. The latest developments—positive legal resolution, strong fundamentals, and decisive indicator alignment—strengthen the bullish view, with traders now watching for a confirmed close above $53.90 as a catalyst for additional upside.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.